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Abstract: Changing from branded drugs to generic alternatives, or between different generic 
formulations, is common practice aiming at reducing health care costs. It has been suggested that 
antiepileptic drugs (AEDs) should be exempt from substitution because of the potential negative 
consequences of adverse events and breakthrough seizures. Controlled data are lacking on the 
risk of substitution. However, retrospective data from large medical claims databases suggest 
that switching might be associated with increased use of AED and non-AED medications, and 
health care resources (including hospitalization). In addition, some anecdotal evidence from 
patients and health care providers’ surveys suggest a potentially negative impact of substitution. 
Well-controlled data are needed to assess the real risk associated with substitution, allowing health 
care professionals involved in the care of patients with epilepsy to make informed decisions. 
This paper reviews currently available literature, based on which the authors suggest that the 
decision to substitute should be made on an individual basis by the physician and an informed 
patient. Unendorsed or undisclosed substitution at the pharmacy level should be discouraged.
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Introduction
Changing from branded drugs to generic alternatives, or switching between different 
generic formulations, is common practice among physicians, pharmacists, and hospital 
formularies. Changes to generic drugs are based on the assumption that generic medi-
cines provide an opportunity to obtain similar treatment at lower costs for patients and 
payers while liberating budgets for financing new, innovative medicines and diagnostic 
or therapeutic procedures. Indeed, pricing studies show that generic medications ensure 
lasting price reductions.1
With antiepileptic drugs (AEDs), in the absence of controlled data, several concerns 
were raised when considering substitution, of which the most important is loss of seizure 
control as a result of changing serum drug levels.2–5 As a result of these potentially 
negative outcomes, several societies and specialist bodies (eg, UK National Institute for 
Health and Clinical Excellence [NICE]6 and the American Academy of Neurology7,8) 
discourage mandatory substitution of AEDs in specific patients and certain situations. 
Furthermore, regulatory bodies in several European countries have issued guidance or 
policies relating to nonsubstitution of certain AEDs, thus acknowledging epilepsy as a 
critical disease. For example, the Medical Products Agency (MPA; Läkemedelsverket) 
in Sweden specifies that lamotrigine, carbamazepine, phenytoin, valproic acid, and 
gabapentin cannot be changed for a generic version,9,10 while the Finnish National Therapeutics and Clinical Risk Management 2009:5 450
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Agency for Medicines (Laakelaitos) does not include 
AEDs on its list of medicines substitutable by generic 
formulations.11
Guidelines have been issued in the absence of well-
controlled data being the gold standard for evaluating this 
question. In the absence of evidence-based decision-making, 
medical claims databases appear to have the highest level 
of unbiased data. These databases are limited by a number 
of factors which are outlined below, though results support 
findings derived from surveys of patients and physicians, 
pharmacokinetic studies, and case reports suggesting an 
overall cautious approach in substitution.
There is broad agreement amongst several professional 
societies (eg, the Deutsche Gesellschaft Für Epileptologie 
and the Italian Chapter of the League Against Epilepsy) 
that stable patients who are seizure-free, or whose seizures 
are well controlled on a given AED, should not be switched 
from branded to generic medication, or between different 
generic formulations, unless the physician considers this to 
be medically necessary and full disclosure is made by the 
treating physician to the patient.12 Furthermore, substitution 
at the pharmacy level should not be performed without the 
physician’s approval and the informed consent of the patient. 
This article reviews presently available data relating to the 
potential medical impact of substitution of a generic AED 
for a branded product or for an alternative generic formula-
tion of the same AED and areas of further research to further 
delineate the risks and benefits of substitution.
Impact of loss of seizure control: 
current data
It has long been suggested that specific disease categories 
should be established in which exemption should be 
granted from any reimbursement policies involving manda-
tory substitution of branded agents with a cheaper generic 
alternative.13 One such category is for so-called “critical 
diseases” (ie, those with potentially serious outcomes if 
therapy should fail, or where polypharmacy may present 
difficulties), and the risk of loss of seizure control means 
that there is a strong case for epilepsy to be included in this 
category.
The occurrence of a breakthrough seizure in a patient 
with well-controlled disease requires seizure control to be 
re-established. Observational data are available from patients 
who have experienced seizures as a result of discontinuing 
AEDs. Though clearly different in its methodology, results 
suggest that regaining seizure control after a breakthrough 
seizure can be a lengthy process.14
A single breakthrough seizure for a seizure-free patient 
has a substantial impact on safety, self-esteem, social inter-
actions, and employment (Table 1).15,16 Another implication 
of a single or more breakthrough seizures is the loss of the 
patient’s driving license. For example, regulations in the 
UK state that patients may not drive after a seizure, and are 
unable to reapply for their license until 12 months after their 
last seizure.17
Clinical relevance of generic 
substitution
In most European counties and the United States, substitu-
tion of second-generation drugs is common and widespread. 
In order to understand the potential risk that a minority of 
patients face, it is important to understand both the clinical 
implications as well as the pharmacokinetic and pharmaco-
dynamic effect of AEDs. Nowadays there is some evidence 
that high plasma levels might be associated with AEs and low 
plasma levels might trigger seizures.18–22 Before substituting 
one product for another, it is important that physicians con-
sider the potential clinical consequences of over- and under-
treatment.23 While over-treatment is associated with adverse 
events, under-treatment may precipitate seizures that, as 
noted above, can destabilize the patient’s condition.
Robust data on the incidence of generic substitution 
(ie, branded–generic or generic–generic) in practice and 
its impact on patients are limited. With the patent expiry 
of a number of AEDs, this issue has greatly increased in 
importance. While no prospective randomized controlled 
trials are yet available, and information on disease 
characteristics, baseline demographics, and reason for 
switch are limited, data from retrospective medical claims 
databases analyses can provide useful data and deserve to 
Table 1 Potential impact of a single breakthrough seizure in a 
patient with well-controlled epilepsy2,5,14,53–57
Impact
impact
Loss of seizure control
Loss of independent-living capabilities
employment problems
Loss of driving licenses
Stigmatization
Loss of confidence
Risk of injury
Hospitalization
Risk of deathTherapeutics and Clinical Risk Management 2009:5 451
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be analyzed. These data supplement case reports and series 
from pharmacist or physician practices, as well as pharma-
cokinetic studies.
Large-scale surveys and medical  
claims database analyses
In the United States, a case-control study with data from 
1,664 patients in the Ingenix LabRx Database—containing 
longitudinal eligibility, pharmacy claims, and medical 
claims data from a US population of managed Medicare, 
Medicaid, and employed commercially insured patients 
with dependents – was performed.24 Cases (individuals with 
epilepsy who received care during 2006 in an ambulance, 
emergency room or inpatient hospital with a primary 
epilepsy diagnosis) were 81% more likely to have been 
switched to a generic formulation compared with control 
patients (those who had a primary epilepsy diagnosis in a 
physician’s office during the same period; odds ratio, 1.81; 
95% confidence interval [CI]: 1.25–2.63). Cases were also 
significantly more likely to be Medicaid recipients than 
controls (4.6% vs 1.8%; p = 0.002); when Medicaid recipients 
were removed from the analysis, the significant difference 
between cases and controls remained.
Data derived from a public payer pharmacy claims 
database in Ontario, Canada, regarding generic substitu-
tion and associated medical and financial consequences, 
were recently published.25 In total, 1,354 patients received 
generic lamotrigine (403 receiving monotherapy and 951 
receiving lamotrigine as part of a polytherapy regimen). Of 
these, 12.9% switched back to branded lamotrigine (11.7% 
in the monotherapy group and 13.4% in the polytherapy 
group). Switch-back rates were higher still for clobazam 
and valproate (Table 2), and were substantially higher than 
for statin (1.5%) or selective serotonin reuptake inhibitor 
(1.9%–2.9%) therapy. In patients who did not switch back 
from generic lamotrigine, the average daily dose was 
initially 255.3 mg, increasing to 271.1 mg while receiving 
the generic product (6.2% increase; p  0.0001). Switching 
to a generic agent, regardless of whether the patient subse-
quently switched back, was also associated with significant 
increases in the use of AED and non-AED concomitant 
medications (+11.0%; p  0.0001 and +15.6%; p  0.0001, 
respectively).
In Ontario, mandatory substitution of generic drugs can 
be circumvented if a physician submits an adverse reaction 
form to the pharmacist, documenting that switching back 
to the branded product is medically necessary. A review of 
71 pharmacies yielded 14 adverse reaction forms.26 In 11 cases 
(79%), loss of seizure control while receiving generic 
lamotrigine was the primary reason for switching back to the 
branded formulation. In one case, anxiety, mood swings and 
dizziness were cited as additional reasons. In eight of 10 cases 
where an outcome was recorded, seizure control was recov-
ered after branded lamotrigine was reinstated. As part of the 
same study, a chart review of data from six physicians (nine 
patients receiving generic lamotrigine; duration, 3–224 days) 
was carried out.26 For eight of the nine patients, loss of seizure 
control was recorded as the reason for switching back to 
branded lamotrigine; seven of these patients regained control 
when switched back to branded lamotrigine.
The Canadian province of Quebec allows the continued 
use of branded drugs – even when a generic alternative 
is available – for up to 15 years after listing in the Régie 
de l’Assurance-Maladie du Québec (RAMQ) formulary. 
Analysis of the RAMQ database (January 2006 to October 
2007) in an open-cohort design, classifying the observation 
into periods of brand, single-generic and multiple-generic 
use, provided information on 948 patients observed for an 
Table 2 Switchback rates in database studies of brand-to-generic switching
Reference  Data source  AED  N  Switch 
back (%)
Andermann et al25 Public–payer database from Ontario, Canada 
(Ontario Drug Benefit claims)
valproate
Clobazam
Lamotrigine
1,770
1,483
1,354
20.9
27.1
12.9
LeLorier et al45 Régie de l’Assurance Maladie du Québec 
database
Carbamazepine
Clobazam
Gabapentin
Lamotrigine
851
1,060
202
671
20.8
44.1
30.9
27.5
LeLorier et al27  Régie de l’Assurance Maladie du Québec 
database
Newer AeDsa  
Older AeDsb
948  14.7 
19.2
Notes: aTopiramate, lamotrigine, gabapentin; bDivalproex, clobazam, clonazepam, valproate, and carbamazepine.
Abbreviation: AeD, antiepileptic drug.Therapeutics and Clinical Risk Management 2009:5 452
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average of 665 days.27 Within one year of observation, newer 
AEDs (topiramate, lamotrigine, and gabapentin) and older 
AEDs (divalproex, clobazam, clonazepam, valproate and 
carbamazepine) showed generic switch rates of 30.5% and 
18.2%, respectively, which were lower than with non-AEDs 
(35.9%). There was also a higher switchback rate for AEDs 
(14.7% and 19.2%) versus non-AEDs (7.8%). Of patients 
receiving generic AEDs, approximately 25%–50% took two 
or more different generic versions of a drug. Compared with 
patients receiving non-AED agents, patients taking AEDs 
were significantly less likely to switch to a generic alternative 
(hazard ratio [HR], 0.77; 95% CI: 0.70–0.84; p  0.0001) but 
more likely to switch back (HR, 1.88; 95% CI: 1.52–2.33; 
p  0.0001). Compared with continuous use of a branded 
AED, the risk of hospitalization was 1.28 times higher after 
single brand–generic switch (p  0.0059) and even more 
pronounced after a generic–generic switch, with an almost 
3.8-fold higher risk (p  0.0001). The risk of head injury 
or fracture for a single brand–generic switch was 1.53 times 
higher, and for multiple generic switches was 5.4 times higher 
(both p  0.0001). Additionally, compared with brand use 
only, single and multiple switches were associated with sig-
nificantly higher pharmacy use (other AEDs and non-AEDs) 
and increased lengths of hospital stay.
As part of the analysis of the Quebec database, data on 
patients switching from branded to generic topiramate were 
also evaluated. Similar to the findings with lamotrigine in the 
Ontario database, substantial increases in use of prescription 
drugs and hospitalizations were reported, particularly in those 
who received more than one generic formulation (Figure 1).27 
Overall, 23% of patients who received generic topiramate 
received at least two different generic versions. After adjust-
ment, multiple generic use was associated with 21% higher 
total health care costs (adjusted cost ratio [CR], 1.21; adjusted 
p = 0.0420), whereas the difference between single generic 
and brand periods was not statistically significant (adjusted 
p = 0.9715). The lower costs of generic topiramate compared 
with the brand were counterbalanced, however, by higher 
costs for other drugs, (single generic versus brand: adjusted 
CR, 0.95; adjusted p = 0.3053; multiple generic versus brand: 
adjusted CR, 1.14; adjusted p = 0.0926) and marginally higher 
costs for medical services (not statistically significant).
Pharmacokinetic studies
Several pharmacokinetic studies, in healthy volunteers and 
patients with epilepsy, have been conducted to compare 
parameters such as maximum serum concentration (Cmax) 
and exposure (area under the curve; AUC) for branded and 
generic AEDs, and many have identified wide variations 
in the pharmacokinetic profiles of some generic formula-
tions (reviewed by Crawford and colleagues).3 Notably, 
some generic formulations of carbamazepine and phenytoin 
have been identified that fail to meet bioequivalence 
standards.15,28–31 More recently, a pilot study was carried out in 
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eight outpatients who reported problems attributed to a switch 
from branded to generic lamotrigine, and one patient who 
requested pharmacokinetic information ahead of a proposed 
switch (all patients had received branded lamotrigine for at 
least two weeks before enrollment).22 Daily blood profiles 
were obtained at 3- or 4-hour intervals on day 3 after admis-
sion, while receiving branded lamotrigine. A second profile 
was then carried out at least seven days after switching to 
generic lamotrigine. In five of the nine patients, lamotrigine 
pharmacokinetic parameters increased or decreased by more 
than 10%. Complaints reported by these patients included 
increased seizure frequency or relapse, as well as ataxia, 
falls and vertigo.
Case reports and case study series
Case reports and case study series are the lowest level of 
evidence and are open to bias to report negative consequences 
only. However, they have often reported an increase in severe 
adverse events after changing to a generic AED.18–20
In an open-label crossover study, 14 patients who had 
been receiving a branded carbamazepine formulation for 
at least 35 days were changed to a generic alternative.18 
Clinically relevant adverse events, including dizziness, 
nausea, ataxia, diplopia, and nystagmus, were reported in 
nine of the 14 patients, occurring on the day of the change 
or one day after. Severe adverse events occurred in seven 
patients. In all but one patient, the occurrence of adverse 
events was correlated with an increased Cmax and AUC of 
carbamazepine and its active metabolite, carbamazepine-10, 
11-epoxide, after changing to the generic formulation.18 
AEDs that have been implicated in increases in seizure 
frequency after generic substitution include phenytoin,21 
carbamazepine,5,18,19,32 valproate,33 and primidone,34 with 
some authors attributing this to reduced bioavailability with 
the generic formulation.
As part of a large survey of AED use in the United States, 
physicians were asked to submit case report forms regard-
ing patients who experienced loss of seizure control after 
switching to a generic AED.35 Fifty patients, well controlled 
on a branded AED (phenytoin, valproate, carbamazepine, 
gabapentin, or zonisamide), subsequently experienced a 
breakthrough seizure or increased seizure frequency after 
switching to the generic alternative without other provok-
ing factors. Of 26 patients in whom serum AED levels were 
known before and after generic substitution, 21 were found 
to have lower levels at the time of the breakthrough seizure 
while receiving generic medication. Within one week of 
seizure, 72% of patients had been switched back to the 
branded product, with 91% switched back within one month. 
At the time of case review, 44 of the 46 patients switched 
back to the branded product had regained seizure control. 
Loss of seizure control had a negative impact on quality of 
life, including loss of driving privileges (n = 30), and missed 
school/work days (n = 9).
Patient and physician surveys 
of generic substitution
To gain insight into the incidence and impact of generic 
prescribing in “real-world” practice, numerous surveys of 
patients and health care professionals have been carried out.
Patient surveys
A study of  general practices in the UK identified 2,285 patients 
with epilepsy who were receiving carbamazepine, phenytoin, 
or sodium valproate.36 A questionnaire was sent to these 
patients, and those who recalled taking a generic agent 
(defined as a drug supplied by a different pharmaceutical 
manufacturer) during the previous two years were inter-
viewed by their practice if they reported a problem with the 
control of their epilepsy after substitution. Of the patients 
contacted, 1,333 (59%) responded, and 251 (19%) of respon-
dents had experienced a change in medication supplier. In 
total, some form of problem (ie, reduced seizure control 
or increased side effects) was reported by 29% of patients 
who changed medication. This included 11% who reported 
“validated” problems (ie, an increase in seizure frequency 
or side effects with no other medical or psychological 
cause identifiable by the GP), of which an increase in side 
effects or “feeling worse” was the most common problem 
(21/27 patients), followed by an increase in seizure frequency 
(8/27 patients) and first seizure in over 12 months (one 
patient). In addition, 10% of patients reported “unproven” 
problems (other likely medical or psychological explanations 
were identified by the GP), while follow-up was incomplete 
in 9%. The majority of problems (88%) were reported in 
patients who were changed from a branded to a generic 
product, or between generic products.
In a Canadian survey of 83 patients with epilepsy, 14 
(17%) reported that they had been changed from a branded 
AED to a generic alternative.37 Of these, two patients (14%) 
reported that they had had problems after the change. In 
a US survey of 82 patients (or their parents), 96% agreed 
that switching between forms of the same AED may cause 
an increase in seizures or adverse effects, with only 38% 
feeling that medication switching is safe.38 In addition, 
43% of patients reported having problems with formulation Therapeutics and Clinical Risk Management 2009:5 454
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switching, and 48% reported knowing other patients with 
problems.
A larger, international survey of  patient opinions regarding 
generic AEDs was carried out in Canada, the UK, Germany, 
France, and Spain in 2004.39 Of 974 patients included in the 
analysis, just over half were aware of the term “generic” 
(52%). In subsequent questions, ”generic” was defined for 
all patients as “a less expensive and clinically similar alter-
native to a name-branded prescription medication.” Overall, 
58% felt uncomfortable about receiving a generic AED. 
Breakthrough seizures were attributed to generic medication 
by 23% of patients.
In a recent US study, 550 patients with epilepsy were 
questioned about their perceptions of generic AEDs.40 
Overall, one-third of patients (34%) linked breakthrough 
seizures with generic substitution, while two-thirds (65%) 
had concerns about the efficacy of generic agents.
Physician surveys
In the Canadian survey described above, 46 neurologists 
were also surveyed about their attitudes towards generic 
substitution of AEDs.37 Only around half of respondents felt 
that generic substitution of various AEDs was safe, although 
values ranged from 30% for lamotrigine to 67% for primidone. 
A larger-scale study was carried out in the United States, in 
which 6,420 neurologists received a postal survey question-
naire; of these, 301 (4.7%) responded.41 Breakthrough seizures 
after changing from a branded AED to a generic alternative 
were reported by 68% of the neurologists who responded, 
while 56% reported an increase in adverse events after 
substitution. When considering a change between different 
generic preparations of the same AED, 33% of neurologists 
reported breakthrough seizures and 27% reported an increase 
in adverse events attributable to a change from one generic 
AED to another. Among the reported consequences of generic 
substitution were an increase in the need for consultations, a 
greater number of sick days, and a higher incidence of injury 
to patients. Perhaps most worryingly, 10% of physicians stated 
that their relationship with the patient had been undermined 
by the change to a generic AED. Neurologists were also ques-
tioned in the study about their responses to generic substitu-
tion, the most common of which was to specify “dispense as 
written” or a similar instruction on future prescriptions.
More recently, 606 physicians who treat patients with 
epilepsy (74% neurologists, including epileptologists, and 
26% GPs) were questioned about perceptions of generic 
medication.40 Concern about an increase in breakthrough 
seizures in patients switched from a branded AED to a generic 
or who are consistently switched among generic formulations 
of the same AED was expressed by 88% of physicians. In 
addition, 55% were “very” or ”extremely” concerned about 
the level of epilepsy control as a result of generic substitution. 
When 312 French private neurologists and hospital specialists 
in epilepsy were questioned, most indicated that they felt 
uncomfortable with generic substitution, with only a few 
actually prescribing generic AEDs.42 Few respondents, 
however, indicated on prescriptions that substitution should 
not be carried out. One-third of participants reported the 
occurrence of breakthrough seizures (n = 70) or new adverse 
events (n = 75) after generic substitution, and 70% stated 
that additional telephone consultations were required with 
patients who had switched.
Physician responses to generic AED substitution were 
also assessed in a cross-sectional, telephone-based survey of 
435 GPs, neurologists and epileptologists in Canada, the UK, 
France, Germany and Spain.39 In total, respondents stated 
that 65% of AED prescriptions were for brand-name drugs, 
particularly in France and Spain, where more than 90% of 
prescriptions were for branded agents. Generic substitution 
without the physician’s consent was opposed by 55% of 
respondents, and 27% believed that a patient had experienced 
a breakthrough seizure as the result of a change to a generic 
agent. Overall, 31% of physicians reported that they felt 
uncomfortable about prescribing generic AEDs.39
Similar results were obtained in an Internet-based survey 
of members of the German, Austrian, and Swiss sections of 
the International League Against Epilepsy, and members 
of the Deutsche Gesellschaft Für Epileptologie.43 Of  2,800 
physicians contacted, more than 600 responded, with 
around 80% reporting experience with generic AEDs. Of 
these, approximately half reported problems with their 
usage, primarily in the form of additional use of health care 
resources (telephone contacts, visits, hospital admissions, 
calls for emergency doctors, or visits to emergency rooms). 
Around half of the physicians also reported that their expe-
riences with generic AEDs had led them to change their 
prescribing behavior, as well as increasing patient counseling 
and blood level monitoring. Current criteria for approval 
of generic AEDs were considered to be inappropriate by 
50% of respondents, while 90% considered it unacceptable 
that pharmacists are able to substitute a generic agent for a 
branded drug without consultation.43
Pharmacist survey
A survey of 112 community pharmacists in the United States 
found that 87% agreed that switching between forms of the Therapeutics and Clinical Risk Management 2009:5 455
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same AEDs may cause an increase in seizures or adverse effects, 
even though 96% felt that medication switching in general was 
safe.38 Half of pharmacists questioned (51%) knew of patients 
who had experienced problems when changing formulations.
Awareness of generic substitution
In patients who experience sudden, unexpected loss of seizure 
control, physicians and pharmacists may look for explana-
tions such as poor compliance with the medication regimen, 
inappropriate dose modification or drug–drug interactions. 
Brand–generic or generic–generic substitution should not, 
however, be overlooked.
Physicians
Physicians may greatly underestimate the number of generic 
prescriptions that are distributed by pharmacists. In a survey 
of physicians attending two major US epilepsy and neurology 
congresses, most estimated that the rate was 30% or 50%.44 
Independent audit revealed, however, that the overall substitu-
tion rate was 68%. In a recent US survey of 660 physicians who 
treat patients with epilepsy, 25% of physicians were unaware 
that a pharmacist may substitute a generic medication for a 
brand prescription without physician consent, even though 
85% of physicians believed that such substitution of AEDs 
without physician consent is medically inappropriate and unac-
ceptable.40 On average, physicians reported that 55% of their 
AED prescriptions used for the treatment of epilepsy specified 
“dispense as written” (brand only), although this practice was 
far more common among neurologists (61% of prescriptions) 
than GPs (36%). In a Canadian survey, there was again some 
lack of information concerning pharmacy dispensing proce-
dures, with 10 of 46 neurologists (22%) unaware that a generic 
could be substituted by the pharmacist even when a brand 
name was specified on the prescription.37 Perhaps surprisingly, 
only 41% of pharmacists in the US survey knew that problems 
resulting from formulation switching should be reported as 
adverse drug events to the US Food and Drug Administration 
(FDA), and only 27% had used the FDA’s MedWatch for 
reporting of safety information and adverse events, even though 
79% of pharmacists were aware of the program.38
Patients
Results from surveys show that awareness of generic pre-
scribing by individual patients is very low. In large US and 
international surveys of patient opinions regarding generic 
AEDs, only 34%–38% of  patients were aware that pharmacies 
could substitute a generic medication without the physician’s 
consent.39,40 Similarly, a US survey of 82 patients found that 
fewer than half (47%) knew that problems with formulation 
switching should be reported as adverse drug events to the 
FDA, and only 6% knew of the FDA MedWatch program.38 
In a Canadian survey of 83 patients with epilepsy, 22% did 
not know whether they had ever been changed from a branded 
drug to a generic alternative.37
Discussion
Until recently, data regarding the clinical effects of brand–
generic or generic–generic substitution were limited to 
single-case or small patient-series reports, patient or phy-
sician surveys. For example, Crawford (2006) stated that 
evidence was “limited,” consisting of “mainly case reports 
with some pharmacokinetic studies.”3 There was also a large 
body of unpublished, anecdotal evidence that substitution 
of AED formulations was associated with efficacy or safety 
issues. Indeed, all the authors of this paper have treated 
patients who have experienced problems with adverse 
events or breakthrough seizures, such as those detailed 
above, after switching between branded and generic or 
between two generic formulations. While this anecdotal 
evidence was highly suggestive of a link between generic 
substitution and adverse effects, there remained a need for 
methodologically robust studies to evaluate the relationship. 
More recently, patent expiry of frequently used AEDs 
has led to increased interest, including generation of more 
robust data to estimate clinical effects of brand–generic or 
generic–generic substitution. While these data are far from 
ideal—double-blind randomized controlled trials are lacking, 
and claims databases do not provide information on disease 
characteristics and lack important patient information (eg, 
seizure frequency, disease duration, etc)—medical claims 
database analyses still provide useful information about the 
care of patients with epilepsy and associated medical costs. 
These recent publications therefore represent some advance 
in the state of knowledge regarding generic substitution when 
compared with the previous, largely anecdotal, evidence.
Initial results from large Canadian database studies 
appear to support the effects of generic substitution that have 
been suspected from anecdotal reports for many years: that 
there may be an apparent association with increased seizure 
frequency, morbidity, and use of health care services, with a 
number of patients requiring a switch back to their previous 
formulation.25,27,45 The risk of seizures, injuries and health 
care use appears to be further increased with generic–generic 
switching. Smaller pharmacokinetic studies have demonstrated 
that patients who switch formulations experience variations 
in serum drug levels that can lead both to over-treatment and Therapeutics and Clinical Risk Management 2009:5 456
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adverse events, as well as under-treatment,18–20,22 which might 
be a possible explanation for the findings discussed above.
Surveys of patients and physicians, while far less robust 
than the large database studies discussed above and open to 
bias, can provide a useful “real-world” view of substitution, 
and appear to provide corroboration for the findings of database 
analyses. One important finding of such surveys is the relatively 
low level of awareness among physicians and patients regarding 
the ability of pharmacists to make generic substitutions without 
the explicit consent of the prescriber and the patient.37,39,40,44 
With this in mind, several European and US professional 
bodies have called for an end to generic substitution of AEDs 
without informed consent of the patient and physician,7,8,12,46–49 
while others, including the Scottish Intercollegiate Guide-
lines Network,50 NICE6 and the Irish Epilepsy Association 
(Brainwave),51 recommend that generic substitution of AEDs 
should not be carried out at all, thus acknowledging epilepsy 
as a critical disease. As noted above, it is important to realize 
that issues with substitution for the individual patient may not 
apply only when switching from a branded product to a generic 
agent, but also when switching from one generic formulation 
to another.27 Furthermore, generic drugs may differ from the 
original branded product and from each other in appearance 
(eg, changes to color or shape), which can lead to confusion 
or even anxiety for patients.36,37,52
Ideally, the effects of generic substitution would be 
evaluated in a prospective manner—such as in randomized, 
controlled trials using, for example, a cross-over design and 
of sufficient duration to overcome natural fluctuations in 
serum AED levels. An enriched population might be most 
likely to show differences if it captured the emergence of 
adverse events as well as seizures. The study would have to 
rely on pharmacokinetic data comparing generics at the upper 
and lower end of bioequivalence. However, whether seizure-
free patients are willing to enter a study with the potential 
hazard of experiencing adverse events and breakthrough 
seizures remains to be seen.
A possible alternative would be a prospective, observa-
tional study in patients considered by their physician to be 
eligible for generic substitution, to include both pharmaco-
kinetic measurements and clinical outcomes. Such a study 
would be easier to conduct as it would reflect current daily 
practice, although it would definitely be hampered by its 
open-label design and dependent on patients’ and physicians’ 
expectations about potential outcomes. Therefore, double-
blinded trial designs with the objective of looking at the 
occurrence of adverse events and/or seizures would be the 
preferred option to investigate this question further.
As the patents of AEDs continue to expire, there will be 
increasing pressure on prescribers and pharmacists to reduce 
medication costs by switching to generic alternatives, or 
between different generic formulations as costs and supplies 
vary. It is important, therefore, that health care workers are 
aware of the potential consequences of substitution and 
consider each patient on an individual basis regarding their 
eligibility for a change of formulation.
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